As the AIDS research community and public health systems locally, nationally and globally focus efforts on preventing HIV transmission and ending the epidemic, it is critical to integrate our efforts across institutions and disciplines, sharing resources among many researchers to achieve the greatest gain in scientific understanding. Our strategic planning process made clear that the greatest contribution of a New York City-based Center for AIDS Research (CFAR) would be achieved by synergizing the scientific strengths, research expertise and clinical resources of three major NYC academic institutions, the Albert Einstein College of Medicine (Einstein), the Rockefeller University (Rockefeller) and Hunter College/City University of New York School of Public Health (CUNY). Thus, the Einstein/Rockefeller/CUNY (ERC)-CFAR was created as a highly synergistic new partnership of non-overlapping complementary resources. The ERC-CFAR links a strong basic and clinical research institution with a large patient base of HIV-infected individuals (Einstein), a globally pre-eminent basic science institution (Rockefeller), and a strong public health/implementation science institution (CUNY) to catalyze research to prevent, treat and eradicate HIV infection and thereby end the epidemic.
Proactive, inclusive and integrated trans-institutional leadership to the ERC-CFAR is provided by a highly experienced and integrated team of Einstein, Rockefeller and CUNY investigators with complementary research and administrative expertise led by the ERC-CFAR Director, Dr. Harris Goldstein (Einstein), and Associate Directors, Dr. Charles Rice (Rockefeller), Dr. Denis Nash (CUNY), Dr. Sarah Schlesinger (Rockefeller) and Dr. Betsy Herold (Einstein). They utilize their scientific expertise and leadership skills to establish a highly interactive, collaborative and inclusive Center for HIV/AIDS Research which mobilizes and engages investigators from their respective institutions in ERC-CFAR programs and initiatives focused on “bench to bedside to community and back to the bench” research to achieve our mission, to arrest the AIDS epidemic.
The overarching goal of the ERC-CFAR is to stimulate, coordinate, and support an integrated multidisciplinary research agenda to achieve our mission, to arrest the AIDS epidemic, through improving utilization of current treatments and developing new therapies, such as potent broadly neutralizing antibodies, for prevention, reducing the incidence of new infections; for treatment, improving treatment outcomes among infected individuals; and for eradication of HIV reservoirs. In addition to developing novel therapeutic approaches, our investigators are optimizing the translation of scientific breakthroughs into reality by identifying and implementing the most effective strategies to deliver treatments shown to be efficacious in clinical and bench research.
In the Media
The New York Times reports that this year’s Lasker-DeBakey Clinical Medical Research Award honors Dr. Charles M. Rice, who developed a system to study the replication of the virus that causes hepatitis C, an advance that has led to safe and powerful new drugs that cure the disease. The award, considered the most coveted American prize in medical science, will be presented on September 23 in New York City (Tuesday, September 13,2016)
Crain’s Health Pulse interviews Dr. Laurie Bauman regarding a collaborative study aimed at controlling the spread of HIV using PrEP, a drug proven to reduce risk. Dr. Bauman is a principal investigator on the study, which includes Einstein, Montefiore and Columbia. She also is director of the Preventive Intervention Research Center and professor of pediatrics. (Friday, July 29, 2016)
The Los Angeles Times interviewed Dr. Michel Nussenzweig regarding new results from a clinical trial show he led that showed that the broadly neutralizing 3BNC117 antibody can significantly delay the HIV from rebounding in patients taken off their current medications. “Using antibodies against HIV could be part of a ‘kick and kill’ strategy, said study co-author Dr. Michel Nussenzweig to kick the virus out of its hiding places and kill it.” (Wednesday, June 22, 2016)
The New York Times interviews Dr. Nir Barzilai, M.D., about his upcoming clinical trial to determine if an existing FDA-approved drug can extend health span. Dr. Barzilai and his collaborators at the American Federation for Aging Research will investigate if metformin, a cheap and commonly used medication to treat type 2 diabetes, can delay the onset of several age-related diseases. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of the Institute for Aging Research at Einstein. (Monday, February 01, 2016).